Thermo Fisher Scientific (NYSE:TMO) today posted fourth-quarter results that beat the overall consensus on Wall Street.
The Waltham, Massachusetts–based laboratory supply company reported profits of $1.7 billion, or $4.17 per share, on sales of $10.7 billion for the three months ended Dec. 31, 2021, for a bottom-line loss of -33.6% on sales growth of 1.42% compared with Q4 2020.
Adjusted to exclude one-time items, earnings per share were $6.54, $1.27 ahead of The Street, where analysts were looking for sales of $9.29 billion.
“We had an outstanding 2021, as we continued to execute our proven growth strategy, powered by our PPI Business System, and operated with speed at scale to help our customers and governments around the world advance their important work,” president and CEO Marc Casper said in a news release. “We exceeded the goals we set out to accomplish in 2021 and delivered for all of our stakeholders.”
Shares in TMO were up 0.79% to $599 in mid-morning trading.